Honz Pharmaceutical Co., Ltd. (300086.SZ)
CNY 5.5
(-0.9%)
CNY 5.5
(-0.9%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 787.6 Million CNY | -15.58% |
| 2022 | 932.96 Million CNY | 3.07% |
| 2021 | 905.13 Million CNY | -10.55% |
| 2020 | 1.01 Billion CNY | 70.76% |
| 2019 | 592.59 Million CNY | 12.47% |
| 2018 | 526.89 Million CNY | 67.1% |
| 2017 | 315.3 Million CNY | -0.48% |
| 2016 | 316.82 Million CNY | 27.63% |
| 2015 | 248.24 Million CNY | 102.67% |
| 2014 | 122.48 Million CNY | 29.8% |
| 2013 | 94.36 Million CNY | -0.7% |
| 2012 | 95.02 Million CNY | -14.22% |
| 2011 | 110.77 Million CNY | 45.73% |
| 2010 | 76.01 Million CNY | 41.83% |
| 2009 | 53.59 Million CNY | -4.17% |
| 2008 | 55.92 Million CNY | 117.75% |
| 2007 | 25.68 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 748.01 Million CNY | -5.87% |
| 2024 Q1 | 794.66 Million CNY | 0.9% |
| 2024 Q3 | 805.33 Million CNY | 7.66% |
| 2023 Q2 | 774.86 Million CNY | -0.56% |
| 2023 FY | 787.6 Million CNY | -15.58% |
| 2023 Q4 | 787.6 Million CNY | 5.53% |
| 2023 Q3 | 746.33 Million CNY | -3.68% |
| 2023 Q1 | 779.25 Million CNY | -16.48% |
| 2022 Q3 | 782.08 Million CNY | -1.35% |
| 2022 Q4 | 932.96 Million CNY | 19.29% |
| 2022 FY | 932.96 Million CNY | 3.07% |
| 2022 Q1 | 852.97 Million CNY | -5.76% |
| 2022 Q2 | 792.78 Million CNY | -7.06% |
| 2021 Q2 | 1.05 Billion CNY | 7.54% |
| 2021 Q4 | 905.13 Million CNY | 1.05% |
| 2021 FY | 905.13 Million CNY | -10.55% |
| 2021 Q1 | 984.75 Million CNY | -2.69% |
| 2021 Q3 | 895.71 Million CNY | -15.42% |
| 2020 Q2 | 793.64 Million CNY | -1.17% |
| 2020 Q3 | 911.67 Million CNY | 14.87% |
| 2020 Q4 | 1.01 Billion CNY | 11.0% |
| 2020 FY | 1.01 Billion CNY | 70.76% |
| 2020 Q1 | 803.06 Million CNY | 35.52% |
| 2019 Q3 | 517.12 Million CNY | -6.57% |
| 2019 Q2 | 553.48 Million CNY | 6.84% |
| 2019 FY | 592.59 Million CNY | 12.47% |
| 2019 Q1 | 518.03 Million CNY | -1.68% |
| 2019 Q4 | 592.59 Million CNY | 14.59% |
| 2018 Q3 | 577.46 Million CNY | 54.07% |
| 2018 Q1 | 298.91 Million CNY | -5.2% |
| 2018 Q2 | 374.8 Million CNY | 25.39% |
| 2018 Q4 | 526.89 Million CNY | -8.76% |
| 2018 FY | 526.89 Million CNY | 67.1% |
| 2017 Q3 | 241.63 Million CNY | -2.04% |
| 2017 FY | 315.3 Million CNY | -0.48% |
| 2017 Q4 | 315.3 Million CNY | 30.49% |
| 2017 Q2 | 246.66 Million CNY | 1.06% |
| 2017 Q1 | 244.07 Million CNY | -22.96% |
| 2016 Q2 | 284.31 Million CNY | -7.02% |
| 2016 Q1 | 305.79 Million CNY | 23.18% |
| 2016 FY | 316.82 Million CNY | 27.63% |
| 2016 Q4 | 316.82 Million CNY | 10.21% |
| 2016 Q3 | 287.48 Million CNY | 1.12% |
| 2015 Q3 | 134.47 Million CNY | 37.0% |
| 2015 Q4 | 248.24 Million CNY | 84.6% |
| 2015 Q1 | 89.85 Million CNY | -26.64% |
| 2015 FY | 248.24 Million CNY | 102.67% |
| 2015 Q2 | 98.16 Million CNY | 9.24% |
| 2014 FY | 122.48 Million CNY | 29.8% |
| 2014 Q4 | 122.48 Million CNY | -8.85% |
| 2014 Q3 | 134.37 Million CNY | 4.11% |
| 2014 Q2 | 129.07 Million CNY | 30.3% |
| 2014 Q1 | 99.05 Million CNY | 4.97% |
| 2013 Q3 | 70.13 Million CNY | -8.48% |
| 2013 Q4 | 94.36 Million CNY | 34.54% |
| 2013 FY | 94.36 Million CNY | -0.7% |
| 2013 Q1 | 74.64 Million CNY | -21.45% |
| 2013 Q2 | 76.63 Million CNY | 2.67% |
| 2012 Q3 | 78.63 Million CNY | -21.34% |
| 2012 Q4 | 95.02 Million CNY | 20.84% |
| 2012 Q2 | 99.97 Million CNY | -16.42% |
| 2012 FY | 95.02 Million CNY | -14.22% |
| 2012 Q1 | 119.62 Million CNY | 7.99% |
| 2011 FY | 110.77 Million CNY | 45.73% |
| 2011 Q2 | 54.58 Million CNY | -49.87% |
| 2011 Q3 | 85.79 Million CNY | 57.17% |
| 2011 Q4 | 110.77 Million CNY | 29.11% |
| 2011 Q1 | 108.89 Million CNY | 43.26% |
| 2010 Q4 | 76.01 Million CNY | 53.25% |
| 2010 Q3 | 49.59 Million CNY | 26.16% |
| 2010 Q1 | 73.35 Million CNY | 36.86% |
| 2010 Q2 | 39.31 Million CNY | -46.4% |
| 2010 FY | 76.01 Million CNY | 41.83% |
| 2009 FY | 53.59 Million CNY | -4.17% |
| 2009 Q4 | 53.59 Million CNY | 0.0% |
| 2008 FY | 55.92 Million CNY | 117.75% |
| 2007 FY | 25.68 Million CNY | 0.0% |